These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 11032912

  • 1. Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.
    Nielsen LL.
    Oncol Rep; 2000; 7(6):1191-6. PubMed ID: 11032912
    [Abstract] [Full Text] [Related]

  • 2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL.
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
    Nielsen LL, Shi B, Hajian G, Yaremko B, Lipari P, Ferrari E, Gurnani M, Malkowski M, Chen J, Bishop WR, Liu M.
    Cancer Res; 1999 Dec 01; 59(23):5896-901. PubMed ID: 10606231
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr 01; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 5. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
    Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL.
    Cancer Chemother Pharmacol; 1999 Apr 01; 44(2):143-51. PubMed ID: 10412949
    [Abstract] [Full Text] [Related]

  • 6. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J, Sato S, Shimada M, Kanamori Y, Itamochi H, Terakawa N.
    Gynecol Oncol; 2002 Feb 01; 84(2):210-5. PubMed ID: 11812076
    [Abstract] [Full Text] [Related]

  • 7. NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model.
    Nielsen LL.
    Oncol Rep; 2000 Feb 01; 7(1):151-5. PubMed ID: 10601610
    [Abstract] [Full Text] [Related]

  • 8. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J.
    Curr Opin Mol Ther; 1999 Aug 01; 1(4):500-9. PubMed ID: 11713766
    [Abstract] [Full Text] [Related]

  • 9. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
    Heise C, Lemmon M, Kirn D.
    Clin Cancer Res; 2000 Dec 01; 6(12):4908-14. PubMed ID: 11156251
    [Abstract] [Full Text] [Related]

  • 10. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
    Grace MJ, Xie L, Musco ML, Cui S, Gurnani M, DiGiacomo R, Chang A, Indelicato S, Syed J, Johnson R, Nielsen LL.
    Am J Pathol; 1999 Dec 01; 155(6):1869-78. PubMed ID: 10595917
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
    Zhang AL, Russell PJ, Knittel T, Milross C.
    Prostate; 2007 Nov 01; 67(15):1630-40. PubMed ID: 17823933
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
    Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D.
    Gene Ther; 2000 Nov 01; 7(22):1925-9. PubMed ID: 11127580
    [Abstract] [Full Text] [Related]

  • 13. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Nov 01; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 14. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
    Mujoo K, Maneval DC, Anderson SC, Gutterman JU.
    Oncogene; 1996 Apr 18; 12(8):1617-23. PubMed ID: 8622881
    [Abstract] [Full Text] [Related]

  • 15. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
    Oakley R, Phillips E, Hooper R, Wilson D, Partridge M.
    Clin Cancer Res; 2002 Jun 18; 8(6):1984-94. PubMed ID: 12060644
    [Abstract] [Full Text] [Related]

  • 16. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS.
    Cancer Res; 2002 May 15; 62(10):2731-5. PubMed ID: 12019144
    [Abstract] [Full Text] [Related]

  • 17. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y, Tokino T.
    Clin Cancer Res; 2009 Jun 01; 15(11):3725-32. PubMed ID: 19458054
    [Abstract] [Full Text] [Related]

  • 18. Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
    Nielsen LL, Gurnani M, Shi B, Terracina G, Johnson RC, Carroll J, Mathis JM, Hajian G.
    Cancer Res; 2000 Dec 15; 60(24):7066-74. PubMed ID: 11156413
    [Abstract] [Full Text] [Related]

  • 19. Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.
    Atencio IA, Avanzini JB, Johnson D, Neuteboom S, Vaillancourt MT, Nielsen LL, Hajian G, Sutjipto S, Sugarman BJ, Philopena J, McAllister DL, Beltran JC, Nodelman M, Ramachandra M, Wills KN.
    Mol Ther; 2001 Jul 15; 4(1):5-12. PubMed ID: 11472100
    [Abstract] [Full Text] [Related]

  • 20. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models.
    Streck CJ, Dickson PV, Ng CY, Zhou J, Gray JT, Nathwani AC, Davidoff AM.
    Clin Cancer Res; 2005 Aug 15; 11(16):6020-9. PubMed ID: 16115947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.